Abliva’s CEO about the phase II study
In December last year, Abliva initiated a potentially pivotal phase II study with KL1333. The candidate is being developed for the treatment of primary mitochondrial disease in adults, a group of rare diseases that lack effective treatment. CEO Ellen K. Donnelly visited BioStock’s studio to tell us more.
See the interview with Abliva’s CEO Ellen K. Donnelly, in English, below.
See Ellen K.Donnelly present Abliva at BioStock Investor Meeting here:
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.
